Idiopathic Myelofibrosis - Symptoms, Causes, Treatment & Prevention

Overview

Idiopathic myelofibrosis (also called primary myelofibrosis or PMF) is a rare chronic blood‑cancer that originates in the bone‑marrow–forming cells (hematopoietic stem cells). In PMF, abnormal megakaryocytes release growth factors that stimulate excess fibrous (scar‑like) tissue to replace the normal marrow. As the marrow becomes fibrotic, it can no longer produce adequate blood cells, leading to anemia, leukopenia, and thrombocytopenia.

PMF belongs to a group of diseases called myeloproliferative neoplasms (MPNs). Unlike secondary myelofibrosis (which develops after long‑standing polycythemia vera or essential thrombocythemia), idiopathic myelofibrosis occurs without a known preceding disorder.

• Who it affects: Most patients are adults > 60 years old, but cases are reported from 20 years onward.
• Gender: Slight male predominance (≈ 55 % male).
• Prevalence: Approximately 0.5–1.5 cases per 100,000 people in the United States and Europe (Mayo Clinic, 2022).^[1]

Symptoms

Symptoms result from marrow failure, splenic sequestration, and the cytokine storm generated by abnormal cells. Not all patients have every symptom; presentation can be subtle.

Constitutional

• Fatigue & weakness: Due to anemia.
• Unexplained weight loss: Often 5–10 % of body weight.
• Night sweats & fever: Low‑grade fever may mimic infection.

Hematologic

• Anemia: Pale skin, shortness of breath on exertion.
• Leukopenia: Increased susceptibility to infections.
• Thrombocytopenia or thrombocytosis: Easy bruising, nosebleeds, or paradoxically, clotting events.

Spleen‑related (splenomegaly)

• Abdominal fullness or early satiety: Enlarged spleen presses on the stomach.
• Pain or a palpable mass in the left upper quadrant.
• Hypersplenism: Over‑active spleen removes blood cells, worsening cytopenias.

Other organ‑specific signs

• Bone pain: Often in the ribs, spine, or pelvis.
• Itching (pruritus): Usually after a warm shower.
• Gynecomastia or hormonal changes: Rare, due to cytokine effects.

Causes and Risk Factors

In idiopathic (primary) myelofibrosis, the exact trigger is unknown, but several molecular abnormalities are identified in > 90 % of cases.

Genetic mutations

• JAK2 V617F: Present in ~ 50‑60 % of patients; activates the JAK‑STAT pathway, driving uncontrolled cell growth.^[2]
• CALR (calreticulin) mutations: Found in 20‑30 % of cases; associated with a more favorable prognosis than JAK2.
• MPL (myeloproliferative leukemia virus) mutations: Less common (~ 5 %).
• Triple‑negative: No JAK2, CALR, or MPL mutation; often linked to poorer outcomes.

Established risk factors

• Age: Risk rises sharply after 60 years.
• Male sex.
• Family history of myeloproliferative neoplasms: Rare but documented.
• Prior exposure to ionizing radiation or chemotherapy: Most relevant to secondary, not primary, disease.

Diagnosis

Diagnosis requires a combination of clinical evaluation, laboratory tests, imaging, and bone‑marrow pathology. The 2016 World Health Organization (WHO) criteria are the current standard.

Laboratory studies

• Complete blood count (CBC) with differential – looking for anemia, leukopenia/leukocytosis, platelet abnormalities.
• Peripheral blood smear – teardrop‑shaped red cells (dacrocytes), nucleated RBCs, immature myeloid cells.
• Serum chemistry – elevated lactate dehydrogenase (LDH) and uric acid, low iron stores.
• Mutational analysis – PCR or next‑generation sequencing for JAK2, CALR, MPL.

Imaging

• Abdominal ultrasound or CT scan – assesses splenomegaly or hepatomegaly.
• Bone‑marrow MRI (optional) – can demonstrate fibrosis without invasive biopsy.

Bone‑marrow biopsy

The definitive test. Features include:

• Grade 2–3 reticulin or collagen fibrosis (MF‑2/3).
• Hypercellular marrow with atypical megakaryocytes (bulbous nuclei, clustering).
• Absence of another myeloid neoplasm or myelodysplastic syndrome.

Prognostic scoring

Two widely used models help estimate survival and guide therapy:

• International Prognostic Scoring System (IPSS): Uses age > 65, hemoglobin < 10 g/dL, leukocyte count > 25 × 10⁹/L, circulating blasts ≥ 1 %, and constitutional symptoms.
• DIPSS‑plus: Adds karyotype abnormalities, platelet count < 100 × 10⁹/L, and transfusion dependence.

Treatment Options

Therapy is individualized based on symptom burden, risk category, and patient preferences. Goals are to control symptoms, reduce spleen size, and improve survival.

Watchful waiting

Patients with low‑risk disease, minimal symptoms, and stable blood counts may be monitored with regular CBCs and physical exams every 3–6 months.

Pharmacologic therapy

• JAK inhibitors (first‑line for symptomatic or splenomegaly):
  • Ruxolitinib – improves spleen volume by ~ 30‑35 % and alleviates constitutional symptoms. FDA‑approved for intermediate/high‑risk PMF (2023 FDA label).^[3]
  • Fedratinib – alternative for patients intolerant to ruxolitinib; also reduces spleen size.
• Hydroxyurea – cytoreductive agent; useful for leukocytosis or thrombocytosis when JAK inhibitors are contraindicated.
• Danazol or anabolic steroids – may improve anemia in select patients.
• Immunomodulatory drugs (lenalidomide, thalidomide) – modest benefit for anemia but limited by neuropathy and thrombotic risk.

Transfusion support

• Red‑cell transfusions for symptomatic anemia.
• Platelet transfusions for severe thrombocytopenia or bleeding.

Procedural interventions

• Splenectomy: Considered when massive splenomegaly causes severe pain, cytopenias, or refractory symptoms. Carries 5‑10 % peri‑operative mortality; risk of post‑splenectomy infections.
• Splenic radiation: Low‑dose (5‑10 Gy) can shrink spleen and improve blood counts for non‑surgical candidates.
• Allogeneic hematopoietic stem‑cell transplantation (HSCT): The only curative option. Recommended for high‑risk patients (IPSS ≥ 2) ≤ 65 years with suitable donor. 5‑year overall survival ranges 40‑55 % (CIBMTR data, 2022).^[4]

Lifestyle & supportive care

• Iron supplementation only if iron‑deficiency documented (avoid unless needed, as iron overload can worsen fibrosis).
• Vaccinations – influenza annually, pneumococcal (PCV20/PPV23), COVID‑19, hepatitis B if at risk.
• Avoid smoking and limit alcohol (both can exacerbate cytopenias).
• Physical activity tailored to energy level – helps maintain muscle mass and bone health.

Living with Idiopathic Myelofibrosis

Chronic disease management focuses on quality of life and monitoring for disease evolution.

Regular follow‑up

• Every 3–4 months for high‑risk or treated patients; every 6–12 months for low‑risk watchful waiting.
• Blood counts, physical exam (spleen size), and symptom questionnaire (e.g., MPN‑Symptom Assessment Form).

Symptom‑relief strategies

• Fatigue: Small, frequent meals; moderate aerobic exercise; consider sleep hygiene and treatment of anemia.
• Early satiety: Eat smaller meals, chew slowly, avoid large fatty foods.
• Itching: Cool showers, topical menthol or calamine, antihistamines; evening antihistamines often help.
• Weight management: Work with a dietitian to maintain a balanced diet while coping with early satiety.

Psychosocial support

• Join MPN patient support groups (Mayo Clinic Connect, Myeloproliferative Neoplasm Alliance).
• Consider counseling or cognitive‑behavioral therapy for anxiety/depression, which affect up to 30 % of patients.^[5]

Monitoring for transformation

~ 10‑20 % of PMF patients can evolve to acute myeloid leukemia (AML). Warning signs include rapidly rising blasts, sudden drop in blood counts, or new‑onset severe fatigue. Prompt evaluation is essential.

Prevention

Because the disease originates from spontaneous genetic mutations, primary prevention is limited. However, some steps may reduce overall risk or mitigate complications:

• Maintain a healthy lifestyle—balanced diet, regular exercise, and avoidance of tobacco.
• Limit exposure to ionizing radiation (e.g., unnecessary CT scans) when possible.
• For individuals with a known familial MPN predisposition, genetic counseling and periodic blood monitoring are advisable.
• Vaccinate against infections that can precipitate marrow stress (influenza, COVID‑19, pneumococcus).

Complications

If left untreated or inadequately controlled, PMF may lead to serious health problems:

• Progression to acute myeloid leukemia (AML): Median survival after transformation < 6 months.
• Severe anemia: Requires chronic transfusions, risk of iron overload.
• Thrombotic events: Deep‑vein thrombosis, portal vein thrombosis, or arterial strokes—particularly in patients with elevated platelets.
• Bleeding: Due to thrombocytopenia and platelet dysfunction.
• Splenic rupture: Rare but life‑threatening in massive splenomegaly.
• Secondary infections: Result from neutropenia or functional asplenia after splenectomy.
• Cachexia and malnutrition: From chronic early satiety and high metabolic demand.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Primary Myelofibrosis.” Updated 2022. https://www.mayoclinic.org/diseases-conditions/primary-myelofibrosis
2. American Society of Hematology (ASH). “JAK2 V617F Mutation in Myeloproliferative Neoplasms.” 2021. https://www.ashpublications.org/hematology
3. EMA & FDA. “Ruxolitinib (Jakafi) Prescribing Information.” 2023. https://www.fda.gov/drugs
4. CIBMTR. “Allogeneic Stem Cell Transplantation for Myelofibrosis – Outcomes 2022.” https://www.cibmtr.org
5. International MPN Working Group. “Psychological Morbidity in Myeloproliferative Neoplasms.” *Blood*, 2020;135(23):2039‑2046.